Better half worked on the approval of J&J #icotrokinra. Happy birthday to Icotyde! My 11 year old made this card! #psoriasis #medicine #drugs #chemistry #IL23
March 18, 2026 at 11:31 PM
Better half worked on the approval of J&J #icotrokinra. Happy birthday to Icotyde! My 11 year old made this card! #psoriasis #medicine #drugs #chemistry #IL23
IL-23 is a highly targeted cytokine vs autoimmune disease.
But here with an oral agent!
@nejm.org #ImmunoSky #MedSky
www.nejm.org/doi/full/10....
But here with an oral agent!
@nejm.org #ImmunoSky #MedSky
www.nejm.org/doi/full/10....
Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents | NEJM
Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the treatment of plaque psoriasis. We conducted a phase 3, double-blind, randomiz...
www.nejm.org
November 5, 2025 at 11:21 PM
IL-23 is a highly targeted cytokine vs autoimmune disease.
But here with an oral agent!
@nejm.org #ImmunoSky #MedSky
www.nejm.org/doi/full/10....
But here with an oral agent!
@nejm.org #ImmunoSky #MedSky
www.nejm.org/doi/full/10....
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
Anti-IL-23R peptide now in oral form! Very successful against psoriasis.
Anti-IL-23R peptide now in oral form! Very successful against psoriasis.
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill ICOTYDE offers an innovative new option for patients with moderate-to-severe plaque psoriasis to address patients cycling on topical therapies in need of systemic treatment
www.jnj.com
March 19, 2026 at 7:07 AM
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
Anti-IL-23R peptide now in oral form! Very successful against psoriasis.
Anti-IL-23R peptide now in oral form! Very successful against psoriasis.
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease www.nature.com/articles/d41...
Protagonist Therapeutics and its partner J&J have reported four phase III wins for icotrokinra in psoriasis and expect to submit the macrocyclic peptide to the FDA later this year
Protagonist Therapeutics and its partner J&J have reported four phase III wins for icotrokinra in psoriasis and expect to submit the macrocyclic peptide to the FDA later this year
April 1, 2025 at 2:25 PM
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease www.nature.com/articles/d41...
Protagonist Therapeutics and its partner J&J have reported four phase III wins for icotrokinra in psoriasis and expect to submit the macrocyclic peptide to the FDA later this year
Protagonist Therapeutics and its partner J&J have reported four phase III wins for icotrokinra in psoriasis and expect to submit the macrocyclic peptide to the FDA later this year
In moderate-to-severe plaque psoriasis, oral icotrokinra led to a skin-clearance response in 50 to 65% of patients at week 16, as compared with 4 to 8% with placebo. The incidence of adverse events was similar in the two groups. Full ICONIC-LEAD phase 3 trial results: nej.md/3WDM6qg
#MedSky
#MedSky
November 5, 2025 at 10:29 PM
In moderate-to-severe plaque psoriasis, oral icotrokinra led to a skin-clearance response in 50 to 65% of patients at week 16, as compared with 4 to 8% with placebo. The incidence of adverse events was similar in the two groups. Full ICONIC-LEAD phase 3 trial results: nej.md/3WDM6qg
#MedSky
#MedSky
New FDA approval: Icotyde (icotrokinra) is now an option for moderate-to-severe plaque psoriasis in those 12 and up. That's a new systemic therapy (affects the whole body) if topical treatments aren't enough!
FDA Approves Icotyde for Moderate-to-Severe Plaque Psoriasis
The U.S. Food and Drug Administration (FDA) has recently approved Icotyde (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis. This new systemic therapy provides an additional optio
www.fda.gov
March 19, 2026 at 8:02 AM
New FDA approval: Icotyde (icotrokinra) is now an option for moderate-to-severe plaque psoriasis in those 12 and up. That's a new systemic therapy (affects the whole body) if topical treatments aren't enough!
Some amazing new data presented at #AAD2025. A new #Tyk2 hits #PASI100 in 50% of patients, #Deucravacitinib offers new hope for patients with #lupus and astounding safety and efficacy of #Icotrokinra for #psoriasis.
Details at: www.healio.com/news/dermato...
#DermSky #RheumSky
Details at: www.healio.com/news/dermato...
#DermSky #RheumSky
March 13, 2025 at 1:58 PM
Some amazing new data presented at #AAD2025. A new #Tyk2 hits #PASI100 in 50% of patients, #Deucravacitinib offers new hope for patients with #lupus and astounding safety and efficacy of #Icotrokinra for #psoriasis.
Details at: www.healio.com/news/dermato...
#DermSky #RheumSky
Details at: www.healio.com/news/dermato...
#DermSky #RheumSky
In moderate-to-severe plaque psoriasis, oral icotrokinra led to a skin-clearance response in 50%–65% of patients at week 16, as compared with 4%–8% with placebo. The incidence of adverse events was similar in the two groups. Full ICONIC-LEAD trial results & Research Summary: nej.md/3WDM6qg
November 10, 2025 at 2:49 PM
In moderate-to-severe plaque psoriasis, oral icotrokinra led to a skin-clearance response in 50%–65% of patients at week 16, as compared with 4%–8% with placebo. The incidence of adverse events was similar in the two groups. Full ICONIC-LEAD trial results & Research Summary: nej.md/3WDM6qg
A phase 3 trial showed that oral Icotrokinra, a peptide targeting IL-23R, improves mod-sev plaque psoriasis in 12+ yrs, involving ≥10% BSA. PMID:41191940, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2504187 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://doi.org/10.1056/NEJMoa2504187
No description available
doi.org
December 31, 2025 at 5:10 AM
For moderate-to-severe plaque psoriasis, biologic therapies are highly effective but are available only by injection, and current oral therapies are often less effective. Research findings from the ICONIC-LEAD phase 3 trial are summarized in a Quick Take video. nej.md/47o15uv
#MedSky #DermSky
#MedSky #DermSky
November 7, 2025 at 2:20 PM
For moderate-to-severe plaque psoriasis, biologic therapies are highly effective but are available only by injection, and current oral therapies are often less effective. Research findings from the ICONIC-LEAD phase 3 trial are summarized in a Quick Take video. nej.md/47o15uv
#MedSky #DermSky
#MedSky #DermSky
New in the November 6, 2025, issue of NEJM:
Survival after Chest-Wall Irradiation in Breast Cancer (SUPREMO phase 3 trial) nej.md/3Jxd3sI
Oral Icotrokinra for Plaque Psoriasis (ICONIC-LEAD phase 3 trial) nej.md/3WDM6qg
#MedSky
Survival after Chest-Wall Irradiation in Breast Cancer (SUPREMO phase 3 trial) nej.md/3Jxd3sI
Oral Icotrokinra for Plaque Psoriasis (ICONIC-LEAD phase 3 trial) nej.md/3WDM6qg
#MedSky
November 6, 2025 at 2:03 PM
New in the November 6, 2025, issue of NEJM:
Survival after Chest-Wall Irradiation in Breast Cancer (SUPREMO phase 3 trial) nej.md/3Jxd3sI
Oral Icotrokinra for Plaque Psoriasis (ICONIC-LEAD phase 3 trial) nej.md/3WDM6qg
#MedSky
Survival after Chest-Wall Irradiation in Breast Cancer (SUPREMO phase 3 trial) nej.md/3Jxd3sI
Oral Icotrokinra for Plaque Psoriasis (ICONIC-LEAD phase 3 trial) nej.md/3WDM6qg
#MedSky
Oral IL-23 inhibitor (that's an immune protein!) approved for psoriasis. In trials, 70% got clear/almost clear skin. Think of it this way: imagine 7/10 people you know seeing big improvements!
FDA Approves Icotrokinra, First Oral IL-23 Inhibitor for Plaque Psoriasis
The U.S. Food and Drug Administration (FDA) has approved ICOTYDE (icotrokinra), a first-in-class oral targeted peptide for adults and pediatric patients aged 12 years and older with moderate-to-severe
www.jnj.com
March 18, 2026 at 8:03 PM
Oral IL-23 inhibitor (that's an immune protein!) approved for psoriasis. In trials, 70% got clear/almost clear skin. Think of it this way: imagine 7/10 people you know seeing big improvements!
𝗙𝘂𝗿𝘁𝗵𝗲𝗿 𝗥𝗲𝗮𝗱𝗶𝗻𝗴
📄 Original Article in NEJM Evidence: Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites eviden.cc/3Lk7kqw
📄 Editorial: Oral Psoriasis Therapy — For Whom and at What Cost and Risk? nej.md/496UAh3
📄 Original Article in NEJM Evidence: Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites eviden.cc/3Lk7kqw
📄 Editorial: Oral Psoriasis Therapy — For Whom and at What Cost and Risk? nej.md/496UAh3
November 5, 2025 at 10:29 PM
𝗙𝘂𝗿𝘁𝗵𝗲𝗿 𝗥𝗲𝗮𝗱𝗶𝗻𝗴
📄 Original Article in NEJM Evidence: Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites eviden.cc/3Lk7kqw
📄 Editorial: Oral Psoriasis Therapy — For Whom and at What Cost and Risk? nej.md/496UAh3
📄 Original Article in NEJM Evidence: Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites eviden.cc/3Lk7kqw
📄 Editorial: Oral Psoriasis Therapy — For Whom and at What Cost and Risk? nej.md/496UAh3
About 50% more patients with plaque psoriasis had at least 90% skin clearance within 6 months with a novel, once-daily pill as compared with a current standard of care, two randomized trials showed. #EADV2025
https://www.medpagetoday.com/meetingcoverage/eadv/117557
https://www.medpagetoday.com/meetingcoverage/eadv/117557
Once-Daily Pill for Psoriasis Gets High Marks in Multiple Studies
Early, durable improvement in skin clearance with novel IL-23 blocker icotrokinra
www.medpagetoday.com
September 20, 2025 at 5:33 AM
About 50% more patients with plaque psoriasis had at least 90% skin clearance within 6 months with a novel, once-daily pill as compared with a current standard of care, two randomized trials showed. #EADV2025
https://www.medpagetoday.com/meetingcoverage/eadv/117557
https://www.medpagetoday.com/meetingcoverage/eadv/117557
Late Breaking abstract from 2025 Amer. Acad. Dermatology (AAD) on the Phase 3 ICONIC-LEAD study showed J&J's oral IL-23 inhibitor (icotrokinra) was superior to deucravacitinib in skin clearance (65% vs 8%) & PASI90 (50% v 4%) at Wk 15 in 684 moderate-to-severe plaque PsO pts
Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm
www.biospace.com
March 12, 2025 at 2:00 PM
Late Breaking abstract from 2025 Amer. Acad. Dermatology (AAD) on the Phase 3 ICONIC-LEAD study showed J&J's oral IL-23 inhibitor (icotrokinra) was superior to deucravacitinib in skin clearance (65% vs 8%) & PASI90 (50% v 4%) at Wk 15 in 684 moderate-to-severe plaque PsO pts
Everyone said peptides were too fragile to be drugs. Protagonist Therapeutics turned them into pills.
https://yespress.io/protagonist-therapeutics?utm_source=bluesky&utm_medium=social via Yespress
https://yespress.io/protagonist-therapeutics?utm_source=bluesky&utm_medium=social via Yespress
Protagonist Therapeutics
The clinical-stage biopharma engineering peptides into medicines - rusfertide, icotrokinra and a platform that makes the fragile molecule behave.
yespress.io
July 16, 2026 at 1:47 AM
Everyone said peptides were too fragile to be drugs. Protagonist Therapeutics turned them into pills.
https://yespress.io/protagonist-therapeutics?utm_source=bluesky&utm_medium=social via Yespress
https://yespress.io/protagonist-therapeutics?utm_source=bluesky&utm_medium=social via Yespress
Johnson & Johnson have announced new icotrokinra (JNJ-2113) data from its comprehensive Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis.
#Psoriasis
psoriasisclub.org/thread-8223....
#Psoriasis
psoriasisclub.org/thread-8223....
Icotrokinra results for new psoriasis pill
psoriasisclub.org
March 8, 2025 at 4:53 PM
Johnson & Johnson have announced new icotrokinra (JNJ-2113) data from its comprehensive Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis.
#Psoriasis
psoriasisclub.org/thread-8223....
#Psoriasis
psoriasisclub.org/thread-8223....
Update: "Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of moderate-to-severe plaque psoriasis.
#Psoriasis
psoriasisclub.org/thread-8322-...
#Psoriasis
psoriasisclub.org/thread-8322-...
Icotrokinra seeks approval for psoriasis
psoriasisclub.org
March 18, 2026 at 1:35 PM
Update: "Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of moderate-to-severe plaque psoriasis.
#Psoriasis
psoriasisclub.org/thread-8322-...
#Psoriasis
psoriasisclub.org/thread-8322-...
Potential 2026 Rheumatology Drugsw/ successful phase III RCTs that will need to be reviewed by regulators:
** deucravacitinib (Sotyktu) Tyk2 inhib for PsA
** Icotrokinra (Icotyde) oral IL-23i for psoriasis
** brepocitinib TYK2/JAK1 inhibitor for dermatomyositis
www.fiercepharma.com/marketing/to...
** deucravacitinib (Sotyktu) Tyk2 inhib for PsA
** Icotrokinra (Icotyde) oral IL-23i for psoriasis
** brepocitinib TYK2/JAK1 inhibitor for dermatomyositis
www.fiercepharma.com/marketing/to...
Top 10 most anticipated drug launches of 2026
Like last year, 2026 appears poised to herald the arrival of multiple mega-blockbusters—albeit on an even grander scale than 2025’s plenty-respectable slate of major rollouts.According to Evaluate’s…
www.fiercepharma.com
February 3, 2026 at 12:00 AM
Potential 2026 Rheumatology Drugsw/ successful phase III RCTs that will need to be reviewed by regulators:
** deucravacitinib (Sotyktu) Tyk2 inhib for PsA
** Icotrokinra (Icotyde) oral IL-23i for psoriasis
** brepocitinib TYK2/JAK1 inhibitor for dermatomyositis
www.fiercepharma.com/marketing/to...
** deucravacitinib (Sotyktu) Tyk2 inhib for PsA
** Icotrokinra (Icotyde) oral IL-23i for psoriasis
** brepocitinib TYK2/JAK1 inhibitor for dermatomyositis
www.fiercepharma.com/marketing/to...
EMA's CHMP recommends first oral IL-23 receptor drug for psoriasis and implant-based treatment for wet AMD
🔎 AI-assisted · sourced analysis
#Underreported #Health
🔎 AI-assisted · sourced analysis
#Underreported #Health
EMA's CHMP recommends first oral IL-23 receptor drug for psoriasis and implant-based treatment for wet AMD
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended marketing authorisation for Icotyde (icotrokinra), the first oral medicine targeting the interleukin-23 receptor for moderate-to-severe plaque psoriasis, and Susvimo (ranibizumab), a refillable…
theuncovered.news
July 26, 2026 at 7:48 AM
EMA's CHMP recommends first oral IL-23 receptor drug for psoriasis and implant-based treatment for wet AMD
🔎 AI-assisted · sourced analysis
#Underreported #Health
🔎 AI-assisted · sourced analysis
#Underreported #Health
This architecture translates directly to unmatched predictive capabilities. Vilya-2 successfully models the precise target interactions of advanced therapeutic molecules, including Icotyde (icotrokinra), and Lipfendra (enlicitide), zolucatetide, and daraxonrasib.
August 3, 2026 at 10:03 PM
This architecture translates directly to unmatched predictive capabilities. Vilya-2 successfully models the precise target interactions of advanced therapeutic molecules, including Icotyde (icotrokinra), and Lipfendra (enlicitide), zolucatetide, and daraxonrasib.
Icotyde (icotrokinra) demonstrated high rates of overall skin, scalp, genital and hand/foot psoriasis clearance, and improvements in nail psoriasis, through 1 year.
#Psoriasis
psoriasisclub.org/thread-8487....
#Psoriasis
psoriasisclub.org/thread-8487....
Icotyde for psoriasis 1 year findings
psoriasisclub.org
May 24, 2026 at 10:29 AM
Icotyde (icotrokinra) demonstrated high rates of overall skin, scalp, genital and hand/foot psoriasis clearance, and improvements in nail psoriasis, through 1 year.
#Psoriasis
psoriasisclub.org/thread-8487....
#Psoriasis
psoriasisclub.org/thread-8487....